Nyrada, Inc. · ASX:NYR
Nyrada — Corporate Update (February 2026)
18 slides from Nyrada's corporate update, Feb 5, 2026
Slide 1: Investor Update Webinar
Investor Update Webinar 5 February 2026 | Sydney, Australia Improving Lives, Offering Hope ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase any securities in NYR,
Slide 3: Nyrada Overview
Nyrada Overview › Clinical-stage biotech company developing TRPC ion channel inhibitors to treat a range of medical conditions › Lead drug candidate – Xolatryp® (formerly NYR-BI03) › Potent 3rd generation TRPC 3, 6 and 7 channel inhibitor › Novel and well-understood mechanism of action › Solid scien
Slide 4: Ischemia Reperfusion – Last Cardiac Frontier
Ischemia Reperfusion – Last Cardiac Frontier “Ischemia Reperfusion Injury is defined as the paradoxical exacerbation of cellular dysfunction and death following restoration of blood flow to previously ischemic tissues. Reestablishing blood flow is essential to salvage ischaemic tissue; however, repe
Slide 5: Large Market Opportunity – Myocardial Ischemia Reperfusion Injury
Large Market Opportunity – Myocardial Ischemia Reperfusion Injury Globally: ~15-20 million ~15% people suffer heart mortality within 30 attack annually days No current FDA approved treatments Effective treatment will improve patient outcomes and reduce high costs associated with long-term care of br
Slide 6: Phase I Clinical Trial
Phase I Clinical Trial Key Results: Xolatryp met its Primary Endpoint with all doses safe and well tolerated, with no dose-limiting, or dose-related safety issues. • 48 healthy participants (36 received drug, 12 received placebo). • Nil SAEs • 10 AEs • All mild or moderate • 5 not related to Xolatry
Slide 7: Phase IIa Clinical Trial
Phase IIa Clinical Trial Key Features: Xolatryp to be assessed for safety and preliminary efficacy in patients with ST- Elevation Myocardial Infarction (STEMI) who undergo primary Percutaneous Coronary Intervention (PCI) Scope (subject to change) • 200 patients dosed (up to approximately; placebo an
Slide 8: Stratification of Patients for Safety and Efficacy Endpoints
Stratification of Patients for Safety and Efficacy Endpoints 8
Slide 9: Clinical Proposition
Clinical Proposition* › Strong relationship between infarct size and poor clinical outcomes, particularly 1-year mortality and heart failure › Reducing infarct size leads better heart muscle performance and clinically meaningful benefits › 5% reduction in infarct size can reduce 12-month heart failu
Slide 10: Origins of TRPC Channel Inhibition
Origins of TRPC Channel Inhibition Lutz Birnbaumer Birnbaumer’s Mice 10
Slide 11: TRPC Channels - Cardioprotection
TRPC Channels - Cardioprotection Cell Type TRPC Activation Effect Xolatryp Inhibition Effect Cardiomyocytes Calcium overload → cell death Prevents damage, preserves function and contractility Endothelial Impaired repair → poor blood flow Enhances vessel repair, reduces inflammation Fibroblasts Excess
Slide 12: R&D Activities
R&D Activities Evolving Pipeline: Xolatryp demonstrated preclinical efficacy: • Myocardial ischemia reperfusion injury • Ischemic stroke • Moderate to severe TBI Literature suggests Xolatryp may additionally have efficacy in: • Oncology • Ischemic reperfusion injury – other organs • Cardiac hypertro
Slide 13: Financial Overview and Outlook
Financial Overview and Outlook Capital position Operating Results Summary › Cash balance of AU$7.12 million at FY2025 FY2024 31 December 2025 (AU$) (AU$) › AU$2.16 million R&D tax rebate expected in respect to FY2025 R&D Costs 4,376,215 2,030,502 (subject to Government Agency Corporate and admin Rev
Slide 14: Investment Proposition
Investment Proposition › Distinguished, high calibre, and globally experienced governing and scientific advisory boards › Global biotech and pharma › Extensive and pioneering TRPC knowledge › Demonstrated preclinical efficacy in multiple therapeutic areas › Significant target markets including for i
Slide 15: Preclinical Study 1
Preclinical Study 1 Key Preclinical Results: Xolatryp showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury • 86% Cardioprotection • 43% increase in left ventricular ejection fraction • 50% increase in fractional shortening Key blood biomark
Slide 16: Preclinical Study 2
Preclinical Study 2 Key Preclinical Results: Xolatryp showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion injury when administered as a short-duration intravenous infusion • 42% Cardioprotection • 88% decrease in arrhythmias at 1 hour • 90% decrease i
Slide 17: Conclusion
Conclusion › Nyrada – the company › Pioneering TRPC channel inhibition therapies to treat a range of medical conditions › AU$7.12 million cash position at end Dec 2025 › AU$2.16 million R&D rebated expected › AU$0.46 million option exercise capital 3QFY2026 YTD › Xolatryp – the lead drug asset › Sol
Slide 18: Contact
@nyrada_inc @nyrada_inc info@nyrada.com www.nyrada.com 18